The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services, has awarded IDT Biologika a 10-year Indefinite Quantity, Indefinite Delivery (IDIQ) contract. IDT will provide process development, manufacturing and characterization of vaccine and biologic products for infectious diseases. The total funding could be up to $80 million over the course of the contract if all project milestones are met.
 
The NIAID contract, which is based upon performance milestones, will support early research and development projects, including GMP manufacturing of Phase I/II clinical material for inclusion in Investigational New Drug (IND) applications and/or Biologic License Applications (BLA). IDT has initially received $88,900 for administrative, technical and management support activities to be conducted during the first year, May 15, 2018 to May 14, 2019. The exact content and scope of each individual project is still to be determined with NIAID.
 
“It is a great honor to be awarded this NIAID contract and we are pleased to support the efforts by the U.S. to develop vaccine countermeasures to address public health threats,” said Andreas Kastenbauer, chief executive officer, IDT Biologika. “IDT has a long standing history and proven track record of developing and manufacturing bacterial and virus-based vaccines, including fill and finish for international governments and a number of pharmaceutical and biotech companies worldwide. Our state-of-the-art manufacturing facilities located in Dessau and Rockville are well positioned to serve the current and future requirements of NIAID.”